Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Janux Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
Date: March 18, 2022 |
| By: | /s/ David Campbell |
|
|
| David Campbell, Ph.D. |
|
|
| President and Chief Executive Officer (Principal Executive Officer) |
Date: March 18, 2022 |
| By: | /s/ Tighe Reardon |
|
|
| Tighe Reardon |
|
|
| Acting Chief Financial Officer (Principal Financial and Accounting Officer) |